89bio has discovered novel pegozafermin for the treatment of nonalcoholic steatohepatitis (NASH) in patients.
Pegozafermin stands out as a leading analog of fibroblast growth factor 21 (FGF21) and offers several advantages, including robust histological data, exceptional tolerability, and convenient dosing. This breakthrough has the potential to address the treatment requirements of patients with NASH, including those with F2/3 fibrosis and those with compensated cirrhosis (F4).
Pegozafermin is a specially designed glycoPEGylated analog of fibroblast growth factor 21 (FGF21) that is currently in development for the treatment of non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG).
FGF21 is a naturally occurring hormone that plays a crucial role in regulating various aspects of lipid metabolism and NASH, including reducing triglyceride levels, managing glycaemic control, addressing steatosis, reducing inflammation, and mitigating fibrosis.
Pegozafermin was specifically engineered using a unique glycoPEGylation technology to extend its half-life while preserving its therapeutic potency.
In a detailed analysis of the data, it was found that 45 percent of patients treated with pegozafermin experienced at least a one-stage improvement in liver fibrosis by week 24 without any worsening of NASH.
